'Exceptional' results in phase III leukemia trial
Science Daily: Pharmacology News
DECEMBER 10, 2023
Leukaemia trial shows 'exceptional' results. Personalized treatment for the most common form of adult leukemia helps patients survive for longer and stay in remission, a phase III trial has found. Adult patients were given a combination of cancer growth blocking drugs over varied durations depending on how rapidly their disease responded. More than 19 in 20 patients were in remission three years after starting treatment -- a significant improvement in progression-free and overall survival comp
Let's personalize your content